We Think CompuGroup Medical Societas Europaea (FRA:COP) Can Manage Its Debt With Ease

The external fund manager backed by Berkshire Hathaway’s Charlie Munger, Li Lu, makes no bones about it when he says ‘The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.’ When we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to ruin. Importantly, CompuGroup Medical Societas Europaea (FRA:COP) does carry debt. But is this debt a concern to shareholders?

What Risk Does Debt Bring?

Generally speaking, debt only becomes a real problem when a company can’t easily pay it off, either by raising capital or with its own cash flow. Ultimately, if the company can’t fulfill its legal obligations to repay debt, shareholders could walk away with nothing. However, a more frequent (but still costly) occurrence is where a company must issue shares at bargain-basement prices, permanently diluting shareholders, just to shore up its balance sheet. Of course, the upside of debt is that it often represents cheap capital, especially when it replaces dilution in a company with the ability to reinvest at high rates of return. The first step when considering a company’s debt levels is to consider its cash and debt together.

View our latest analysis for CompuGroup Medical Societas Europaea

What Is CompuGroup Medical Societas Europaea’s Net Debt?

The chart below, which you can click on for greater detail, shows that CompuGroup Medical Societas Europaea had €329.6m in debt in March 2019; about the same as the year before. However, it also had €44.3m in cash, and so its net debt is €285.3m.

DB:COP Historical Debt, July 30th 2019
DB:COP Historical Debt, July 30th 2019

A Look At CompuGroup Medical Societas Europaea’s Liabilities

The latest balance sheet data shows that CompuGroup Medical Societas Europaea had liabilities of €251.8m due within a year, and liabilities of €447.5m falling due after that. Offsetting these obligations, it had cash of €44.3m as well as receivables valued at €146.9m due within 12 months. So it has liabilities totalling €508.0m more than its cash and near-term receivables, combined.

Since publicly traded CompuGroup Medical Societas Europaea shares are worth a total of €3.46b, it seems unlikely that this level of liabilities would be a major threat. Having said that, it’s clear that we should continue to monitor its balance sheet, lest it change for the worse.

We measure a company’s debt load relative to its earnings power by looking at its net debt divided by its earnings before interest, tax, depreciation, and amortization (EBITDA) and by calculating how easily its earnings before interest and tax (EBIT) cover its interest expense (interest cover). The advantage of this approach is that we take into account both the absolute quantum of debt (with net debt to EBITDA) and the actual interest expenses associated with that debt (with its interest cover ratio).

We’d say that CompuGroup Medical Societas Europaea’s moderate net debt to EBITDA ratio ( being 1.6), indicates prudence when it comes to debt. And its strong interest cover of 23.7 times, makes us even more comfortable. Importantly, CompuGroup Medical Societas Europaea grew its EBIT by 53% over the last twelve months, and that growth will make it easier to handle its debt. When analysing debt levels, the balance sheet is the obvious place to start. But ultimately the future profitability of the business will decide if CompuGroup Medical Societas Europaea can strengthen its balance sheet over time. So if you’re focused on the future you can check out this free report showing analyst profit forecasts.

Finally, a business needs free cash flow to pay off debt; accounting profits just don’t cut it. So it’s worth checking how much of that EBIT is backed by free cash flow. Over the most recent three years, CompuGroup Medical Societas Europaea recorded free cash flow worth 63% of its EBIT, which is around normal, given free cash flow excludes interest and tax. This free cash flow puts the company in a good position to pay down debt, when appropriate.

Our View

CompuGroup Medical Societas Europaea’s interest cover suggests it can handle its debt as easily as Cristiano Ronaldo could score a goal against an under 14’s goalkeeper. And the good news does not stop there, as its EBIT growth rate also supports that impression! We would also note that Healthcare Services industry companies like CompuGroup Medical Societas Europaea commonly do use debt without problems. Looking at the bigger picture, we think CompuGroup Medical Societas Europaea’s use of debt seems quite reasonable and we’re not concerned about it. After all, sensible leverage can boost returns on equity. Above most other metrics, we think its important to track how fast earnings per share is growing, if at all. If you’ve also come to that realization, you’re in luck, because today you can view this interactive graph of CompuGroup Medical Societas Europaea’s earnings per share history for free.

If you’re interested in investing in businesses that can grow profits without the burden of debt, then check out this free list of growing businesses that have net cash on the balance sheet.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.